Navigation Links
Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
Date:9/13/2012

or metastatic NSCLC who have an EGFR mutation.1  Patients not previously treated with an EGFR targeted therapy as well as those previously treated with these agents may be eligible for the afatinib EAP.  As a single-arm trial, afatinib will not be compared to another anti-cancer therapy.1  Enrollment criteria are available on clinicaltrials.gov and include patients with:1

  • Locally advanced or metastatic NSCLC1
  • Positive test for EGFR mutation(s)1
  • Performance status between 0 and 21

Afatinib is not approved by the FDA; its safety and efficacy have not been established.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.  The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  

If you or someone you know is interested in participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com.  If you are a healthcare provider and are interested in learning more about BI clinical trials in oncology, please visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals,
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
2. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
3. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
7. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
8. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
9. Henry Schein Announces New $500 Million Credit Facility
10. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
11. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... Jan. 22, 2015 Increasing sophistication among enterprise buyers ... localization purchasing in 2015, says Moravia CMO, ... recent study by market research firm Common Sense Advisory, ... for their translation and localization needs. "From a language ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... continuance needed to reduce cardiovascular,risks, ROCHESTER, Minn., ... therapy for enlarged prostates experience significant,surges in blood ... heart attack or,stroke, according to new research findings ... Clinic-led study of 185 consecutive patients who received,transurethral ...
... designed to validate drug targets for the fatal,neurodegenerative ... April 8, 2008 The ALS,Therapy Development Institute ... agreement with the Allen Institute for Brain Science ... using diseased tissues from a,preclinical animal model of ...
Cached Medicine Technology:Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 2Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 3ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 2ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... two sets of brothers with autism, Johns Hopkins scientists ... to be linked very specifically to the severity of ... interacting protein 1), is a blueprint for a traffic-directing ... brain cells across which chemical signals flow. ...
... A study led by researchers at the University of Michigan ... drug compounds they developed shrank tumors, with few side effects. ... cancer, looked at two compounds designed to activate a protein ... a significant number of human cancers. In some cases, it ...
... Machinery (ACM) has named Takeo Kanade, the U.A. and ... at Carnegie Mellon University, the 2010 winner of the ... computer vision and robotics. , The Newell Award, named ... School of Computer Science, recognizes career contributions that have ...
... cancer is the second most common cancer among women, with ... estrogen over a long period of time is one factor ... One way a woman can combat this risk factor ... with the activity of estrogen. Now, researchers at Fox ...
... Reporter , TUESDAY, April 5 (HealthDay News) -- In ... study, researchers report that risks to postmenopausal women who ... ended the treatment. The study found that ... and blood clots, which were elevated while they were ...
... April 6 (HealthDay News) -- Poor overall health seems ... survivors, according to the results of a new study. ... breast cancer survivors participating in the After Breast Cancer ... shortly after diagnosis, and follow-up occurred an average of ...
Cached Medicine News:Health News:Gene linked to severity of autism's social dysfunction 2Health News:Gene linked to severity of autism's social dysfunction 3Health News:CMU's Takeo Kanade wins ACM/AAAI Award for career contributions to computer vision, robotics 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 3Health News:Overall Health May Be Key to Beating Breast Cancer 2
... Operation: , Standby: All toggle switches at off ... pulse/s); 10 s (1 pulses/10 s) , Tetanus: ... pulses/s) , Train-Of-Four: Single (4 pulses/2 s); repeat ... Output Current: Adjustable from 0-70 mA(HI range) 0-6.0mA ...
... of Operation: , Double Burst : 2 60-ms bursts ... 1 s (1 pulse/s) , Tetanus: 50 Hz ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: Adjustable ... Monophasic pulses (200-us duration) , Indicators: Battery LED (green) ...
... Modes of Operation: , Standby: A standby ... stimulus pulses. , Twitch: 1 s (1 pulse/s) ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Square Wave Monophasic pulses (200-us duration) , Indicators: ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
Medicine Products: